Based on the earnings call transcript, I anticipate a modestly positive short-term impact on Johnson & Johnson's stock price. Key positives include solid operational sales growth of 1.8%, strong pharmaceutical performance (+6.4% operational growth), and raised full-year guidance. However, there are some offsetting concerns including ongoing McNeil Consumer Healthcare remediation costs doubling from $0.06 to $0.12 EPS impact and continued softness in medical device markets. Management's confident tone and the strategic benefits of the Merck REMICADE settlement should provide support. The balanced mix of positives and modest headwinds suggests a mildly positive stock reaction over the next 1-2 weeks.

[1]